# Cytokinetics Incorporated (CYTK) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $72.72, market value $10.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Cytokinetics Incorporated reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 149.4×**. Each dollar of revenue is priced at 149.4×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -5.7%** (5-yr avg -6.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Net margin: -891.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: 119.0%**. A 119.0% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 113.1%**. Return on all capital, debt included, is 113.1%: comfortably above what that capital costs.
- **Return on assets: -62.8%**. Each dollar of assets produces -62.8% of profit.

## Growth
- **Revenue growth (1 yr): 376.6%** (3-yr -2.4%/yr, 5-yr 9.5%/yr). Revenue grew 376.6% over the last year, against 9.5% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -24.3%**. Earnings per share fell 24.3%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: net cash**. Cytokinetics Incorporated holds more cash than debt.
- **Altman Z-score: 0.91**. A Z-score of 0.91 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Cytokinetics Incorporated does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (20 analysts). 20 analysts cover Cytokinetics Incorporated; the consensus is strong_buy, with an average price target of $109.90 (+51% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 46.2%** (YTD 14.4%, 3-mo 1.7%). The shares are up 46.2% over twelve months including dividends.
- **From 52-week high: -17.7%** (54.0% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 0.74** (volatility 45%). Beta of 0.74 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CYTK · Page: https://foliofundamentals.com/stocks/cytk

Not investment advice.